解读生殖系生物标志物检测中的TP53镶嵌变异：对肿瘤学护士的启示
Deciphering TP53 Mosaic Variants on Germline Biomarker Testing: Implications for Oncology Nurses.
作者信息
Grissom Alyssa, Mahon Suzanne M
机构信息
Alyssa Grissom.
Suzanne M. Mahon.
出版信息
Clin J Oncol Nurs. 2025 May 19;29(3):201-206. doi: 10.1188/25.CJON.201-206.
Abstract
Germline biomarker testing of the TP53 gene can produce confusing results including mosaicism or clonal hematopoiesis of indeterminate potential (CHIP). When noninformative results are reported, additional testing is usually.
摘要
TP53基因的种系生物标志物检测可能会产生令人困惑的结果，包括嵌合体或不确定潜能的克隆性造血（CHIP）。当报告无信息结果时，通常需要进行额外检测。
相似文献
1
Deciphering TP53 Mosaic Variants on Germline Biomarker Testing: Implications for Oncology Nurses.
Clin J Oncol Nurs. 2025 May 19;29(3):201-206. doi: 10.1188/25.CJON.201-206.
2
Clinical classification and molecular interpretation of germline pathogenic TP53 variations detected by multigene panel testing in patients with possible cancer predisposition.
Mol Genet Genomics. 2025 Apr 24;300(1):45. doi: 10.1007/s00438-025-02250-w.
3
Evaluation of Variants Detected on Peripheral Blood or Saliva Testing: Discerning Germline From Somatic Variants.
JCO Precis Oncol. 2021 Nov;5:1677-1686. doi: 10.1200/PO.21.00278.
4
Clinical management of TP53 mosaic variants found on germline genetic testing.
Cancer Genet. 2024 Jun;284-285:43-47. doi: 10.1016/j.cancergen.2024.04.002. Epub 2024 Apr 23.
5
TP53 germline testing and hereditary cancer: how somatic events and clinical criteria affect variant detection rate.
Genome Med. 2025 Jan 14;17(1):3. doi: 10.1186/s13073-025-01429-5.
6
Interpretation of ambiguous TP53 test results: Mosaicism, clonal hematopoiesis, and variants of uncertain significance.
J Genet Couns. 2024 Aug;33(4):916-926. doi: 10.1002/jgc4.1789. Epub 2023 Sep 16.
7
Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
Breast Cancer Res. 2019 Sep 18;21(1):107. doi: 10.1186/s13058-019-1193-1.
8
Low Allele Frequency Variants Identified on Germline Multi-Gene Panel Testing for Cancer Predisposition Can Suggest the Presence of Constitutional Mosaicism.
Clin Cancer Res. 2025 Jul 1;31(13):2814-2823. doi: 10.1158/1078-0432.CCR-24-4105.
9
Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional TP53 Status.
Cancer Epidemiol Biomarkers Prev. 2022 Aug 2;31(8):1621-1629. doi: 10.1158/1055-9965.EPI-21-1296.
10
A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next-generation sequencing hereditary pan-cancer panel are acquired somatically.
Hum Mutat. 2020 Jan;41(1):203-211. doi: 10.1002/humu.23910. Epub 2019 Sep 23.
本文引用的文献
1
TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review).
Int J Mol Med. 2025 Jan;55(1). doi: 10.3892/ijmm.2024.5448. Epub 2024 Oct 25.
2
Causes of Clonal Hematopoiesis: a Review.
Curr Oncol Rep. 2023 Mar;25(3):211-220. doi: 10.1007/s11912-023-01362-z. Epub 2023 Jan 31.
3
Mosaicism in Tumor Suppressor Gene Syndromes: Prevalence, Diagnostic Strategies, and Transmission Risk.
Annu Rev Genomics Hum Genet. 2022 Aug 31;23:331-361. doi: 10.1146/annurev-genom-120121-105450.
4
Oncology Nurse Practitioners in Genetics: Examining Scope of Practice and Competence.
Clin J Oncol Nurs. 2022 Apr 1;26(2):141-145. doi: 10.1188/22.CJON.141-145.
5
Risk assessment and genetic counseling for Lynch syndrome - Practice resource of the National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer.
J Genet Couns. 2022 Jun;31(3):568-583. doi: 10.1002/jgc4.1546. Epub 2022 Jan 9.
6
Evaluation of Variants Detected on Peripheral Blood or Saliva Testing: Discerning Germline From Somatic Variants.
JCO Precis Oncol. 2021 Nov;5:1677-1686. doi: 10.1200/PO.21.00278.
7
Myeloid Malignancies: Recognizing the Risk of Germline Predisposition and Supporting Patients and Families.
Clin J Oncol Nurs. 2021 Oct 1;25(5):519-522. doi: 10.1188/21.CJON.519-522.
8
Clonal Hematopoiesis: From Mechanisms to Clinical Intervention.
Cancer Discov. 2021 Dec 1;11(12):2987-2997. doi: 10.1158/2159-8290.CD-21-0901.
9
Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting.
Biochim Biophys Acta Rev Cancer. 2021 Aug;1876(1):188556. doi: 10.1016/j.bbcan.2021.188556. Epub 2021 Apr 29.
10
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw. 2021 Jan 6;19(1):77-102. doi: 10.6004/jnccn.2021.0001.
Zotero 插件